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Abstract
Mechanism-based pharmacokinetic-pharmacodynamic (PK/PD) modelling is the standard computational technique for
simulating drug treatment of infectious diseases with the potential to enhance our understanding of drug treatment
outcomes, drug deployment strategies, and dosing regimens. Standard methodologies assume only a single drug is used, it
acts only in its unconverted form, and that oral drugs are instantaneously absorbed across the gut wall to their site of action.
For drugs with short half-lives, this absorption period accounts for a significant period of their time in the body. Treatment
of infectious diseases often uses combination therapies, so we refined and substantially extended the PK/PD methodologies
to incorporate (i) time lags and drug concentration profiles resulting from absorption across the gut wall and, if required,
conversion to another active form; (ii) multiple drugs within a treatment combination; (iii) differing modes of action of drugs
in the combination: additive, synergistic, antagonistic; (iv) drugs converted to an active metabolite with a similar mode of
action. This methodology was applied to a case study of two first-line malaria treatments based on artemisinin combination
therapies (ACTs, artemether-lumefantrine and artesunate-mefloquine) where the likelihood of increased artemisinin
tolerance/resistance has led to speculation on their continued long-term effectiveness. We note previous estimates of
artemisinin kill rate were underestimated by a factor of seven, both the unconverted and converted form of the artemisinins
kill parasites and the extended PK/PD methodology produced results consistent with field observations. The simulations
predict that a potentially rapid decline in ACT effectiveness is likely to occur as artemisinin resistance spreads, emphasising
the importance of containing the spread of artemisinin resistance before it results in widespread drug failure. We found that
PK/PD data is generally very poorly reported in the malaria literature, severely reducing its value for subsequent re-
application, and we make specific recommendations to improve this situation.
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Introduction
Most human infections are currently treatable by drugs. Clinical
trials remain the gold standard, empirical approach guiding drug
deployment policy and practical issues such as dosing regimes.
However in silico simulations based on computational predictions
of drug treatment outcome have the potential to play a vital
ancillary role in designing and guiding these deployment practices.
Accurate simulations can rapidly investigate the consequences of
putative changes in deployment practices such as changes in
regimen (dosage level, frequency and duration of treatment) and
can investigate and potentially quantify the threat posed by the
evolution of drug resistance. The methodology used to investigate
such factors in silico is mechanism-based PK/PD modelling, whose
basic methodology and range of applications was recently reviewed
by Czock and Keller [1]. In essence, this approach incorporates
existing PK and PD parameters estimates into differential equations
to calculate the decline in drug concentration after treatment, then
converts this into a pathogen killing rate to find how pathogen
number declines after treatment and whether the infection is
eventually cleared. Note the distinction between PK/PD mecha-
nism based modelling (the subject of this manuscript) which uses
existing PK estimates to simulate drug treatment, and PK
parameter estimation models (usually using non-linear analysis)
which are applied to human clinical data to actually produce the PK
estimates; a recurring theme of this manuscript is that the former
fails to fully utilise all the data produced by the latter and we
describe the computational extensions required to achieve this.
PK/PD mechanism-based modelling assumes a single drug is
instantaneously present in the patient after treatment (the drug
absorption and conversion processes often reported in PK
estimation models of human data are ignored) and that pathogens
are killed by the drug in its unaltered form [1]. In practice, drug
combinations are now mandatory for the treatment of many
infections, including the ‘big three’ infective killers HIV, TB and
malaria so the single-drug PK/PD methodology needs to be
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updated to reflect these policies. Many drugs also have short half-
lives so the time taken for their absorption (across the gut in the
case of oral regimens) may be a significant period relative to half-
life and needs to be incorporated into the methodology. Finally,
many drugs undergo conversion in the human (often in the liver)
to other active forms that also kill the pathogens. This manuscript
describes the computational extensions required to update the
standard mechanistic-based modelling approach to allow for
multiple drugs within a combination, and their absorption/
conversion phases. We then illustrate their application to the
current batch of first line antimalarial drugs, the artemisinin-based
combination therapies (ACTs).
Malaria caused by Plasmodium falciparum, is one of the top three
infective killers of humans with an estimated 0.75 to 1.5 million
deaths per annum [2]. ACTs are now the WHO recommended
first-line treatment for uncomplicated malaria [3]. The deploy-
ment of these combination therapies was designed to slow or even
prevent the evolution of drug resistance which has, historically,
been a potent threat to successful malaria treatment; delays in
changing policy led to the widespread retention of ineffective drugs
and acrimonious accusations of ‘medical malpractice’ aimed at
such august institutions as the World Health Organisation [4] and
the malaria community must prevent any similar situation arising.
However, the policy of deploying ACTs worldwide has lead to
increasing levels of artemisinin-tolerance and possibly artemisinin-
resistance in Plasmodium falciparum being reported on the Cambo-
dia-Thailand border [5,6,7,8,9] leading to intense speculation
about how this will affect the current and future effectiveness of
ACTs (e.g. [10,11]). It is not possible to directly observe the
consequences of antimalarial drug resistance until it is too late, so
the best approach is to develop the best possible in silico models to
help guide deployment policies aimed at maintaining long-term
effectiveness of these key anti-infective drugs. We therefore apply
our updated in silico PK/PD modelling methodology to explicitly
investigate two front-line ACTs and the public health conse-
quences of increasing tolerance and resistance. Accurate PK/PD
modelling has two further important applications. Firstly, it can
generate accurate simulations of field data upon which methods of
analysis can be developed and refined [12]; the underlying
parameters of interest are often unknown in field data but are easily
recovered from simulated data enabling the performance of statistical
tests to be gauged. Secondly, they can be used to investigate real-life
situation that cannot be ethically addressed in the field, an obvious
example being poor adherence to a treatment regimen.
Methods
Mathematical extensions of the basic model
We use mechanistic PK/PD modelling [1] as previously
described in Winter & Hastings [13] with the four key extensions
outlined below.
Pharmacokinetics – incorporating the absorption,
conversion and elimination of drugs
Standard PK/PD models [1] and their subsequent application
to malaria [13,14,15,16,17] have previously assumed the drugs are
instantaneously present in the serum at time t = 0, are not
converted to any other form and decay at a rate Ct =C0e
-kt, where
Ct is the drug concentration at time t and k is the terminal
elimination rate. This assumption is questionable for ACTs as
their absorption and subsequent conversion to its active metabolite
dihydroartemisinin (DHA) occur over a time period of 1–2 hours,
roughly equivalent to their half-life (Figure S1). To address this
assumption we track the time course of artemisinin absorption and
conversion as illustrated in Figure 1 i.e. absorption across the gut
(component A) into the serum (component B) at rate x, its
elimination from the body at rate y or its conversion to the active
metabolite (DHA) (component C) at rate z and the subsequent
elimination of DHA from the body at rate k.
The drug-dependent killing function, f(C), was described using
the standard Michaelis-Menton equation
f Cð Þ~Vmax. C
n
CnzIC50
n
 
ð1Þ
where C is the drug concentration (mg/l) which decays over time,
Vmax is the maximal drug-killing rate (per day), IC50 is the
concentration at which 50% of the maximal killing rate occurs
(mg/l) and n is the slope of the dose response curve. The problem
is therefore to find how C varies over time following treatment so
that it can be incorporated into Equation 1.
We use a standard one-compartmental model (Figure 1) that
appears appropriate for constituents of current ACTs (Text S1), to
track the changes in concentration over time. To avoid confusion,
we note that ‘‘one compartment’’ is used in the standard PK sense
i.e. only one body compartment (in this case, serum) is investigated
besides the gut. The change in drug concentration occurring for
each component over time (allowing for complications caused by
the presence of the drug/metabolite from previous dosages) can be
described by three differential equations
dA
dt
~{Ax ð2Þ
dB
dt
~Ax{By{Bz ð3Þ
dC
dt
~Bz{Ck ð4Þ
To find the amount of converted and unconverted drug in the
serum at time t, Equations 3 and 4 were integrated using laplace
Author Summary
Pharmacokinetic-pharmacodynamic (PK/PD) models of
infectious diseases provide vital insights into the effective-
ness of drug treatments (including the optimal dosage
level, frequency and duration) by explicitly relating drug
concentration after treatment to a pathogen kill rate, and
ultimately the models describe whether an infection is
likely to be cleared. Furthermore, they can address issues
such as poor patient compliance and the spread of drug
resistance that are too expensive and/or unethical to
determine in the field. Despite their potential, the
methodologies used in previous PK/PD models have been
based upon the assumptions that only one drug is used in
treatment, that the drug is immediately available in its
active form at the site of action, and that the parent drug is
not further converted to active metabolites. These
assumptions severely limit the application of such models.
We therefore extend the methodology to remove these
assumptions and use this model to investigate two first-
line treatments of malaria. The model accurately replicated
field data and was then used to predict the impact of
increasing drug tolerance and resistance on treatment
outcome. We identified key PK/PD data that can, and
should, be measured and reported in future field studies to
maximise the predictive ability of mathematical models.
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transformations [18] (Text S1). Integrating Equation 3 gives
B tð Þ~ x DzA’ð Þ
x{ yzzð Þð Þ e
{ yzzð Þt{e{xt
 
zB’e{ yzzð Þt ð5Þ
where B(t) is the amount (mg) of unconverted drug in the serum at
time t, A9 is the amount (mg) of drug in the gut at the immediate
end of the previous time step (time steps correspond to the time
between dosages, described in Text S1) i.e. at t=0 (A9=0 if this is
the first dose of a multi-dose regimen), D is the drug dosage (mg)
given and B9 is the amount (mg) of unconverted drug in the serum
at the immediate end of the previous time period i.e. at t=0
(B9=0 if it is the first dose). Inclusion of any drug left over from the
previous time step (denoted A9, B9 and C9) is essential when
including repeat dosages.
Integrating Equation 4 (Text S1) gives
C tð Þ~ zx DzA’ð Þ e
{kt
yzz{kð Þ x{kð Þz
e{qt
k{ yzzð Þð Þ x{ yzzð Þð Þz
e{xt
k{xð Þ yzz{xð Þ
 
z
zB’
yzz{kð Þ e
{kt{e{ yzzð Þt
 
zC’e{kt

MC
MB
ð6Þ
where C(t) is the amount of converted drug present in the serum, k
is the elimination rate of the converted drug, C9 is the amount (mg)
of converted drug in the serum at the immediate end of the
previous time step (C9=0 for the first dose) and M represents the
molecular weight of both the unconverted drug (MB) and
converted drug (MC). We are tracking drugs in mg so the ratio
of the molecular weights of species B and C, MB and MC
respectively, are required to account for the changes in molecular
weight that occur during conversion.
The drug-dependent killing described in Equation 1 required
the amount of drug to be converted to a concentration (mg/l).
This was found by dividing the amount of drug by the volume of
distribution (l) which is the weight of the patient W, multiplied by
the volume of distribution Vd per kg. The value of Vd differs
between the drugs so VdB and Vdc represent volumes of distribution
for drug forms B and C respectively.
The concentration of component B at time t, CB(t), is therefore
CB tð Þ~ B tð Þ
W .VdB
ð7Þ
and the concentration of component C at time t, CC(t) is
Cc tð Þ~ C tð Þ
W .VdC
ð8Þ
The use of Laplace transformations in PK is relatively well
established [18] so it would be straightforward to extend the
calculations for increasing numbers of compartments, drug forms
and conversion elimination routes.
The existence of additional compartments in PK estimation
models can be taken as an example. To recap, PK/PD mechanism
based modelling of malaria requires drug concentrations in the
‘blood’ compartment but all PK estimation models try to include
additional compartments where drugs can go; for example a drug
may go into a ‘‘fat’’ compartment with fluxes between the blood
and fat compartments. PK estimation models decide whether
additional compartments are justified by using an information
criterion (usually AIC). The problem is that PK estimation
modelling is not straightforward and a fair amount of subjective
judgement may be required. This subjectivity, combined with
different datasets, may result in different analyses of the same drug
fitting 1 or 2-compartment models [19]. When using the model it
is important that researches maintain consistency in the PK model
structures (i.e. assuming one or two compartments). For example,
PK parameters derived from a two-compartment model should be
incorporated into a PK/PD model that also uses a two-
compartment structure. The use of Laplace transforms to
incorporate 2 compartmental models is illustrated in the Text
S1; users wishing to use a 2 compartmental model can therefore
replace equations 5 and 6 obtained above for a one compartment
model with Text S1 equations 1.20 and 1.21 obtained from a 2-
compartment model.
Pharmacodynamics – Parasite killing by multiple drugs
The PK/PD modelling now allows for artemisinin absorption
and conversion (described above), so the ability to track more than
two drug concentrations simultaneously and convert them into a
drug-killing rate is crucial. This feature is absent from previous
pharmacological models of malaria, which track only a single drug
[1] although we previously extended the methodology to track up
to two drugs [13]. Existing pharmacological models typically use a
standard differential equation [1] to find a mathematical
description for the rate of change in total parasite growth and
death rates
Figure 1. The standard one-compartment pharmacokinetic model. A standard PK one-compartment model allowing for absorption of a drug
from the gut (component A) at rate x, into the unconverted form in the serum (component B) where it is eliminated at a rate y and converted into an
active form (DHA in this example; component C) at rate z. DHA is then eliminated at rate k.
doi:10.1371/journal.pcbi.1003151.g001
ð6Þ
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dP
dt
~P a{f Ið Þ{f Cð Þð Þ ð9Þ
where P is the number of parasites in the infection, t is time after
treatment (days), a is the parasite growth rate (per day), f(C)
represents the drug-dependent rate of parasite killing which
depends on the drug concentration C, and f(I) the killing resulting
from the hosts background immunity.
As antimalarial drugs are now typically deployed as combina-
tion therapies and as each drug may affect parasites in its
unconverted and/or converted forms, predicting the changing
numbers of parasites requires an expansion of Equation 9
dP
dt
~P a{f Ið Þ{
Xr
d~1
f Cdð Þ
 !
ð10Þ
where r is the number of drugs, the drug effect f(Cd) is the effect of
each drug, d. Note that we regard each active entity as a distinct
‘‘drug’’. For example artemether-lumefantrine (AR-LF) includes
three drug forms lumefantrine (LF), artemether (AR) (unconvert-
ed) and its active metabolite DHA (dihydroartemisinin). Note that
Equation 10 assumes drugs kill independently; this is discussed
further below.
Integrating Equation 10 allows us to predict the number of
parasites at any time, t, after treatment with any number of drugs.
This was done by first integrating Equation 9 using the separation-
of-variables technique
1
P
dP~ a{f Ið Þ{f Cð Þ½ dt ð11Þ
Integrating both sides of Equation 11 gives
ðt
0
1
P
dP~
ðt
0
a{f Ið Þ{f Cð Þ½ dt
so
ln Pt½ {ln P0½ 
~
ðt
0
adt{
ðt
0
f Ið Þdt{
ðt
0
f Cð Þdt
~at{a0{f Ið Þt{f Ið Þ0{
ðt
0
f Cð Þdt
Taking the exponential of both sides (and noting that a times
0= 0) gives
Pt
P0
~e a{f Ið Þð Þt{
1
e
Ð t
0
f Cð Þdt
so
Pt~P0.e
a{f Ið Þð Þt
.
1
e
Ð
f Cdð Þ.dt
~P0e
a{f Ið Þð Þte{
Ð t
0
f Cð Þdt ð12Þ
The problem is now to integrate f(C). Assuming there are r
separate drugs/metabolites with antimalarial activity. In this case,
f(C) becomes
f Cð Þ~
Xr
d~1
f Cdð Þ ð13Þ
So for each drug/metabolite d we need to calculate its
concentration over time Cd using the compartment model
Equations (7 and 8) and the substitute Cd into the killing rate
equation
f Cdð Þ~ V
d
max
.Cd
n
Cd
nzIC50
n ð14Þ
Note in Equation 14, Vdmax is the maximum drug killing Vmax for
drug d.
Substituting Equation 13 into 12 gives
Pt~
P0e
a{f Ið Þð Þt
P
r
d~1
e
Ð t
0
f Cdð Þdt
ð15Þ
or, equivalently,
Pt~P0e
a{f Ið Þð Þt P
r
d~1
e
{
Ð
f Cdð Þ ð16Þ
Note that Cd may be a complicated expression (including
Equations 7 and 8) and so
Ð
f Cdð Þ has to be integrated
numerically. As before [13], if the predicted parasite number (Pt)
falls below 1 we assume the infection has been cleared and the
patient cured, immunity is currently ignored (see Winter &
Hastings [13] for further discussion).
Modelling drug killing when two or more drugs are
present
These computational extensions to the mechanistic PK/PD
modelling allow for the presence of two or more drug forms
simultaneously present in the human host, and active against the
infection. It therefore becomes necessary to consider and specify
how these drug forms interact in their effect against the parasites.
There appears to be four main computational choices.
Independent modes of action. This is the mode of action
explicitly developed above and summarised in Equation 16. Most
drug combinations are designed to contain drugs with indepen-
dent modes of action, so this is a common scenario and would be
revealed by drugs having additive action in pharmacodynamic
studies [20].
Non-independent action. The total drug action may be
greater than, or less than, that expected from the sum of the two
drugs independently. This is commonly referred to as ‘synergy’ or
‘anatogonism’ but see Chou [20] for a fuller discussion of the
dangers inherent in using these terms. It is difficult to even define
these terms [20], still less quantify them, so an empirical approach
based on data obtained from isobolograms [21] would have to be
used to convert drug concentrations into killing.
Identical modes of action. This seems plausible if there are
different, but structurally similar, forms of same drug. One
computational possibility is simply to use the sum of their
concentrations in Equation 1 i.e.
Improving Pharmacokinetic-Pharmacodynamic Modeling
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f CxzCy
 	
~Vmax.
CxzCy
 	n
CxzCy
 	n
zIC50
n
 !
ð17Þ
Where x and y are the two forms. Problems arise if Vmax or IC50
differ between the two forms. The maximal killing rate may
plausibly be the same for each form but it is entirely plausible that
structural differences between the forms alter binding of the drugs
and hence their IC50 values. It is difficult to compute the joint
killing under these circumstances because it is difficult to envisage
how to weight the differing IC50 values.
Dominant form killing. This is a computational compro-
mise. The amount of killing of each related drug form over a time
period is calculated and the higher killing rate used in the
calculations. The underlying premise for this approach is that
although related drugs may differ in their IC50s due to minor
structural differences (see above), they are likely to have identical
effects once present at saturating concentrations (i.e. achieving
maximal kill rates according to the Michaelis-Menton Equation 1)
because they share the same killing mechanism. If both drugs are
present at very low concentrations then kill rate is zero, if one or
both are present at very high, saturating, concentrations then
killing is equal to their common maximal kill rate. The only
problematic situation is where both drugs are present at
concentrations resulting in intermediate kill rates. This approach
is particularly useful for rapidly eliminated drugs that are
essentially either present at full effect or absent so that periods of
time with both drug concentrations producing intermediate kill
rates can be essentially ignored (see, for example, Figure S2). This
is the approach we shall use for artemisinins in the analyses
described below. So, for example, when modelling the artemisi-
nins, the drug killing for both forms (i.e. the parent drug and the
active metabolite) were calculated during each time step and the
drug form with the higher parasite killing was used to update
parasite numbers at the end of the time step. As specific examples,
either drug killing rate could be used when simulating therapeutic
outcome in the patient described by Figure S2A, while artemether
kill rate would be used in patients described on Figure 2B, while
DHA kill rates would be used in patients whose PK characteristics
resulting in them maintaining higher levels of DHA than
artemether (example not shown).
Modelling artemisinin combination therapies
Pharmacological ‘mechanism-based’ modelling [1] has been
used previously to investigate key features of antimalarial drug
treatment either as monotherapies [14,15,16,17] or with recent
emphasis on the current generation of ACTs [13]. We have
previously touched upon the potential consequences of increasing
artemisinin resistance using standard pharmacokinetic-pharmaco-
dynamic (PK/PD) modelling techniques [13] however, as
mentioned in the paper, the model relied heavily on two main
assumptions built in to the existing methodology. First, that all
drugs are instantaneously absorbed and, if appropriate, converted
to their active metabolites. Whilst this may be reasonable for drugs
with a long half-life it is not practical for drugs like the artemisinins
where absorption and conversion times are almost equal to their
short half-lives. The second assumption, that no more than two
drugs could be present simultaneously, was reasonable when
modelling the ACTs if both drugs were instantaneously absorbed
and converted. However, conversion of the artemisinins requires
that the artemisinins be modelled as two separate component
drugs i.e. the parent drug and the DHA metabolite together with
the partner drug and so modelling the ACTs requires a minimum
of three drugs be tracked simultaneously. Here we have addressed
the methodological challenges of incorporating the absorption and
conversion phases of drugs into PK/PD modelling while
simultaneously tracking the concentration of more than two
drugs, a feature absent in previous pharmacological models
[14,15,16].
The PK/PD model parameters required to simulate treatment
are given in Table S1 and described in the Text S1. The PK
extensions for the artemisinins required additional parameters
describing the drug absorption rate across the gut, the conversion
rate to DHA and the elimination of DHA from the body (Figure 1).
These parameters and their associated distributions can be found
in Table S1 with details of model calibration and validation
included in the Text S1. Variation in model parameters was
previously [13] added assuming a coefficient of variation of 30% in
all parameters. In reality, some parameters are much more
variable [22] while others maybe less so. We now incorporate
more appropriate levels of variation into the PK/PD parameters
using drug specific distributions thus making results more
compelling for specific ACTs. To validate the model’s predictive
ability, the maximum serum concentration (Cmax) and time to
achieve Cmax (Tmax) were compared to field data (Text S1).
The methodology described above now allows for the action of
both the unconverted and converted forms of the artemisinins.
However, given that they have similar modes of action their effect
on parasite numbers is unlikely to be additive (as is assumed in
Equation 11). As such, the drug effect, f(C), for each of the
artemisinin forms was calculated each time-step but only the
dominant form (i.e. parent drug or active metabolite) with the
greater drug killing effect was used to compute the number of
parasites in the next time step. Activity, and hence killing, of
artemisinins and the partner drug were assumed to be indepen-
dent.
A major change was made to the artemisinin maximal drug kill
rate (Vmax). Previous estimates of the Vmax [13,23,24] have been
based upon the assumption that drug killing is maximal
immediately after treatment and remains so for 48 hours after
treatment. This is quantified by the parasite reduction ratio (PRR);
a ratio of the number of parasites at time of treatment scaled by
their number 48 hours after treatment. So, assuming the decline in
parasitaemia is first order, the parasite count (Pt) at any given time
(t) is given by
Pt~P0e
{Vt ð18Þ
where P0 is the number of parasites present at the start of
treatment.
This appears to be reasonable for drugs given at relatively high
doses with a long half-life because the maximal killing will extend
over the 48 hours after treatment. However, it is unrealistic for the
artemisinins whose short half-lives mean parasites are typically
only exposed to high concentrations of artemisinins during the first
6–8 hours following treatment (Figures S1 and S2). The steady
decline in parasite numbers after this period presumably reflects
dead or dying parasites being cleared by host mechanisms. PK/
PD modelling of drug effect assumes deaths only occur in the
presence of the drug (i.e. 6–8 hours post-treatment) hence the
need for this increased kill rate. So, given PRR=P0/Pt [23] (where
Pt is usually assumed to be 48 hours), the relationship between
PRR and parasite killing rate Vmax is
Vmax~{
1
t
ln
1
PRR
 
ð19Þ
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Figure 2. Panels A–F, changes in drug failure rates associated with increasing drug resistance. Changes in failure rates associated with
either increasing AS/AR IC50 (panels A–B), increasing DHA IC50 (panels C–D) or simulating increasing both AS/AR and DHA IC50 (panels E–F). Left-
hand column includes AS-MQ treatment and the right-hand column AR-LF treatment. Note that failure rates for monotherapies are shown as columns
to the immediate right of the x-axis.
doi:10.1371/journal.pcbi.1003151.g002
Improving Pharmacokinetic-Pharmacodynamic Modeling
PLOS Computational Biology | www.ploscompbiol.org 6 July 2013 | Volume 9 | Issue 7 | e1003151
When t is assumed to be 48 hours and PRR is 104 then the
maximal artemisinin drug kill rate (Vmax) is 4.6 as used
previously by ourselves and others [13,23]; we now consider
that value inappropriate because a 6 hour burst acting at a kill
rate of 4.6 would achieve a PRR of well below 104 .
Consequently, we assume artemisinin maximal drug killing
occurs only during the 6 hours when the drugs are actually
present at therapeutic concentration (Figures S1 and S2), so
achieving a PRR of 1000 (White [23] gives a range of 103 to 105
for the artemisinins) requires Vmax to be 27.6. Note, if the
maximal drug killing is assumed to occur over 8 hours and the
PRR is assumed to be 10,000 (within the range reported in
White [23]) Vmax again equals 27.6. Consequently our artemi-
sinin maximum killing rate is approximately 7-fold higher than
in previous simulations.
Two treatment combinations were investigated, artesunate-
mefloquine (AS-MQ) and AR-LF, both are highly effective ACTs
currently used to treat malaria. Variation in how humans
metabolise the drug and parasite drug sensitivity was added to
the model parameters (Table S1) using parameter specific
estimates of co-efficient of variation, CV. The technical details
regarding parameter variability are included in the Text S1.
The extended pharmacokinetic-pharmacodynamic (PK/PD)
model can then be implemented to address a critical feature of
current ACT deployment: how is the observed increase in
artemisinin tolerance likely to affect the long-term effectiveness
of ACTs? The crucial operational question is whether there is
likely to be a sudden catastrophic decrease in ACT effectiveness, a
gradual decline or, a best case scenario, a margin of safety such
that we can have relatively large increases in artemisinin
tolerance/resistance before ACT failures start to increase?
The partner drugs, LF and MQ, are currently largely effective
monotherapies if administered correctly (although MQ in south
east Asia may be problematic) so increasing artemisinin resistance
would, by definition, have little or no impact on therapeutic
outcome. To avoid this trivial case, we investigated how increasing
levels of artemisinin resistance impacted treatment failure rates if
resistance to the partner drug was already present or spreading.
When modelling MQ treatments the MQ IC50 values were either
1-, 2-, 5-, 10-, 15-, 20- or 25-fold greater than the current default
value (Table S1) and when modelling LF treatments LF IC50
values were either 1-, 2-, 5-, 10-, 20-, 25- or 50-fold greater than
the current default value (Table S1). Resistance to artemisinins was
investigated in two ways. First by increasing the IC50 of the AS,
AR or DHA (the active metabolite) independently and then by
assuming the IC50s of the parent species and DHA were
completely correlated i.e. the IC50s were increased simultaneously
by the same amount. This was necessary because it is not clear
whether parasites will evolve resistance independently to the
artemisinin entities or whether there will be substantial cross-
resistance to different entities (see later discussion) The IC50 range
of both artemisinin forms included one value 10-fold smaller than
the mean and values 1-, 20-, 40-, 80- or 100-fold greater than the
mean.
Details of implementation are in the Text S1. For each of the
10,000 patients simulated the model recorded whether an
infection (with one clone) was cleared and, if so, the parasite
clearance time (PCT; defined as the time taken for an infection to
fall below the limit of microscopic detection, which was assumed to
be 108). This was done first for the partner drugs without the
artemisinin component, i.e. as monotherapies, to give a baseline
failure rate. Then, by comparing the results of the monotherapy
with those of the ACTs we were able to quantify the ability of the
artemisinin component to reduce failure rates and PCTs.
Results
The artemisinin drug concentration profiles of the model are
consistent with those measured in the field (discussed in Text S1
and Figure S1). Analysis of both ACTs showed that adding an
artemisinin to a partner drug reduced failure rates below that of
the monotherapy regardless of the initial levels of partner drug
resistance, the latter being achieved through varying the partner
drug IC50 value (Figure 2); the only exception was the trivial case
when partner drugs were fully effective as monotherapies. For
AS-MQ, the exact proportion of failures prevented by the
artemisinin component was dependent on the initial level of
resistance to the partner drug. Regardless of whether the IC50s of
the artemisinins were correlated, adding an artemisinin at its
default IC50 value to a partner drug reduced failure rates by
between 70 and 90%. This is a relative reduction, for example, a
50% reduction is equivalent to fall in failure rates from 40% to
20% or from 12% to 6% (Figure 2, panels A, C and E). This is
consistent with field observations that adding AS to MQ reduced
the absolute risk of failing treatment but did not result in a fully
effective ACT [25]; this has also been observed for other failing
monotherapies not modelled here (chloroquine, amodiaquine,
sulfadoxine-pyrimethamine) [25]. The results also show that the
addition of AR to LF monotherapies reduced failure rates to zero
when modelling the mean parameter values (Figure 2, panels B,
D and F).
Figure 2 shows the failure rates of the ACTs when the IC50s of
the two artemisinin drug forms were either varied independently
(Figure 2, panels A to D) or varied simultaneously (Figure 2, panels
E and F). When the IC50s of the artemisinin drug forms were
varied independently increasing the IC50 of either had very little
effect in the failure rates (Figure 2, panels A, B, C and D). This was
particularly clear for AR-LF treatments where increasing either
AR or DHA IC50 caused no measurable increase in drug failure
rates (Figure 2, panels B and D). This occurs because resistance to
one form is compensated by continued sensitivity to the other form
because both forms are potentially capable of high rates of parasite
killing (Figure S2). Increasing AS IC50 alone also had little effect
on the AS-MQ failure rates (Figure 2, panel A), again highlighting
the importance of its active metabolite on parasite survival. When
DHA IC50 was increased by 20-fold in AS-MQ treatment
(Figure 2, panel C), treatment failures increased by 25 to 65%
(relative increase) depending on the level of resistance to the
partner drug. This is the only time increasing either the
artemisinin drug forms alone affected treatment outcome and
further DHA IC50 increases (above 20-fold) had little further
effect on treatment outcome (Figure 2, panel C). Failure rates to
AS-MQ assuming the artemisinin drug forms were uncorrelated
(Figure 2, panels A and C) remained lower than those seen when
assuming they were correlated (Figure 2, panel E) thus implying
both artemisinin drug forms are still playing an active role in
parasite killing.
Further DHA IC50 increases above 20-fold had no discernable
effect on treatment outcome and failure rates remained lower than
those seen when the IC50’s were correlated thus implying that
while not as potent as AR and DHA it still plays an active role in
parasite killing. For both ACTs, increases in failure rate as a result
of increasing artemisinin resistance were much larger if the IC50s
of the artemisinin drug forms were simultaneously increased.
Rapid loss of protection was most noticeable for AS-MQ with
small IC50 increases (20 and 40-fold), well within the range of
natural variation [22], increasing failure rates by 65–70%
(Figure 2, panel E). Loss of protection was more gradual following
AR-LF treatments (Figure 2, panel F) but both ACTs showed
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failure approaching those of the of the monotherapies as
artemisinin IC50s increased to 100-fold greater than the mean.
The PCT appears to be determined predominantly by the level
of resistance to the artemisinin component with the initial level of
partner drug resistance being relatively unimportant (Figure 3).
This was particularly evident following AR-LF treatment where
increasing the IC50 of LF had no discernable effect on PCT
(Figure 3, panels B and D) while increasing MQ resistance only
caused the PCT to vary by up to one day (Figure 3, panels A and
C). When the IC50s of the two artemisinin species were increased
simultaneously, the addition of artemisinin to the monotherapy
reduced PCTs by approximately 2 to 3 days for both ACTs. As
seen with the treatment failures (Figure 2), increasing the IC50 of
AS/AR or DHA independently had little/no effect on PCT
(Figure 3, panels A to D) and PCT did not approach that of the
monotherapy because the other artemisinin species retained its
effectiveness. When the IC50s were increased simultaneously both
artemisinin species lost their effectiveness (Figure 3, panels E and
F) while the PCT increased almost linearly with increasing
artemisinin resistance and approached the PCTs seen with
monotherapies (Figure 3, panels E and F).
Discussion
The extended PK/PD mechanism based modelling was applied
to ACTs and produced results and predictions consistent with field
data on failure rates [25] and increasing PCT associated with
resistance. The main operational concern surrounding the
evolution of artemisinin resistance is that it will lead to clinical
failure in patients treated with ACTs [26]. Obviously, if the
partner drug is effective as a monotherapy, then the presence or
absence of artemisinin resistance has no clinical effect. Problems
arise as resistance spreads to the partner drugs, a process slowed by
the addition of an artemisinin [27]. The results clearly show that
adding AS to a failing drug (MQ) reduced the treatment failure
rates by up to 90% (relative reduction) but did not result in a fully
effective ACT (Figure 2, panel E). This observations is in line with
the findings of the International Artemisinin Study Group who
performed a meta-analysis of individual patients from 16
randomised trials (n = 5948) studying the effect of adding AS to
either CQ, AQ, SP or MQ [25]. While the total population failure
rates were reduced by 42–65% when averaged across all drug
regimens, the addition of AS to MQ monotherapy reduced failure
rates by approximately 90–95% [25]. The results for AR-LF show
that the addition of AR with default IC50 values was sufficient to
save a failing LF monotherapy by reducing failure rates to ,1%
for all levels of partner drug resistance regardless of whether the
IC50s of the AR and DHA are increased simultaneously or
independently (Figure 2, panels B, D and F). However, this
observation was much more difficult to validate than those of AS-
MQ as there is almost no published data on the in vivo efficacy of
LF monotherapy and so it is impossible to quantify the proportion
of failures averted specifically by the addition of AR. We also note
that for both ACTs, only when the IC50s were correlated did
increasing the IC50 eventually lead to failure rates approximately
equal to those of the monotherapy therefore removing any benefit
afforded to the partner drug by the artemisinin. These occurred
after 50–100 fold increases in artemisinin IC50 which is large, but
around the same magnitude as the natural variation observed in
field isolates [22]. The key question is whether the IC50s are
correlated; field data suggest they are (Text S1).
Increasing PCTs are currently being observed in the field
[7,26,28,29,30]; Dondorp et al. [31] for example, show that
parasites resistant or tolerant to artemisinins take 3 or 4 days to
parasites as compared with less than 2 days for artemisinin
sensitive parasites; this pattern was also apparent in the results
presented here (Figure 3). The simulated results showed the initial
level of resistance to the partner drug had very little effect on the
PCT and whilst this may seem strange it can be explained
relatively easily. While the partner drug is undeniably important
when determining the treatment outcome (i.e. success or failure),
the PCT is determined almost solely by the short-lived but fast-
acting artemisinin component, which causes a rapid decline in
parasite numbers but is not present long enough to completely
clear the parasite load [13]. As with dug failure rates, PCT only
approached those of the monotherapies when the IC50s were
increased simultaneously again consistent with field data that the
IC50s are correlated (Text S1). For both ACTs, PCT began to
increase after relatively small increases in artemisinin IC50 of 20-
to 40-fold (within the range of natural variation [22]).
The results shown on Figure 2 illustrate an important factor not
generally recognised when considering how resistance may arise to
artemisinins and other drugs whose converted and unconverted
forms are both active: if resistance arises to only one form, then the
other form may retain sufficient activity to compensate. This is
well illustrated by AR-LF in Figure 2 where increasing resistance
to either AR alone (Figure 2B) or DHA alone (Figure 2D) has
virtually no impact on failure rates which only start to escalate if
resistance occurs simultaneously to both forms (Figure 2F). It is
therefore essential to consider whether mutations that encode
resistance to one form are likely to simultaneously encode cross-
resistance to the other form (so that IC50s are correlated), or
whether the mutations are specific to individual drug forms (in
which case IC50s are uncorrelated). When considering the
likelihood of cross-resistance, it is important to realise that cross-
resistance and mode of drug action are related, but distinct
entities. Drugs with identical modes of action may show complete
cross-resistance if mutations occur at their site of action which
prevents both/all forms of the drug from binding therefore
blocking their activity. Alternately, resistance may emerge through
mutations that alter the drugs’ ability to reach or accumulate at
their site of action. Malaria is often characterised by the latter
where mutations in membrane transporters, notably mdr and crt,
are implicated in resistance to a range of antimalarial drugs [32].
These transporters depend more on the chemical scaffold (charge
and structure) of the drug than its active site so it is not a priori
certain that cross-resistance will inevitable occur between a parent
drug and its active metabolite. A lack of cross resistance would be
hugely beneficial as it means parasites would have to evolve
resistance to both forms of the drug but, unfortunately, our
simulations suggest a model of complete cross resistance provides
the best fit to the malaria observations that IC50s are likely to be
correlated (discussed further in SI).
Drug IC50 values are estimated either from parasites taken
from a patient’s primary infection or from laboratory isolates. The
IC50 values of the artemisinins and their active metabolite DHA
vary widely in the literature and their reported values appear to be
highly dependent on the source from which they were estimated.
For example, Brockman et al. [33] show the mean IC50 of AR was
approximately 4-fold higher than DHA (4.83 and 1.22 respective-
ly) when measured in patients from Thailand but were approx-
imately equal (3.4 and 3.6 in 1996 and 3.1 and 4.0 in 1998
respectively) when measured in K1 laboratory isolates. The 4-fold
lower DHA IC50 measured in patients may result in a higher level
of effectiveness of DHA in their patient population. What is not
generally realised is that both artemisinin components are
potentially important in determining treatment outcome; for
example Saralamba et al. [34] simply stated that in their patients
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Figure 3. Panels A–F, changes in parasite clearance times associated with increasing drug resistance. Changes in parasite clearance
times (PCT) associated with either increasing AS/AR IC50 (panels A–B), increasing DHA IC50 (panels C–D) or simultaneously increasing both AS/AR
and DHA IC50 (panels E–F). Left-hand column includes AS-MQ treatment and the right-hand column AR-LF treatment. Note that PCTs for
monotherapies are shown as columns to the immediate right of the x-axis.
doi:10.1371/journal.pcbi.1003151.g003
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‘‘the total drug exposure of AS was ,10% that of DHA’’ and so
choose to ignore the parasiticidal effect of AS. This may be true on
average, but there is huge variation in how patients metabolise
different forms of the drug so it entirely plausible that some
patients will slowly convert artesunate but rapidly clear DHA, in
which case the former would have the larger killing effect. In
particular, changing IC50 simply translates into how long the drug
is killing at near-maximal rates in the few hours following
treatment (Figure S2). Importantly, this means that artemisinin
therapy given as artesunate or artemether has an inherent
therapeutic safety margin: If one component of the artemisinin
is metabolised quickly or has a particularly high volume of
distribution, there is still a second active component present within
the patient that is likely to retain therapeutic effectiveness.
Increasing tolerance/resistance to artemisinins was modelled
using the standard assumption that it will arise through increased
IC50 values. Artemisinin resistance may be atypical in this respect
as it appears to manifest through increased clearance times of
parasites following treatment with unchanged IC50, possible due
to the drug(s) having activity against a more restricted range of
stages in the malaria cell cycle (see below). The mechanistic
approach assumes instantaneous killing of parasites irrespective of
their stage, so deceased activity against some stages would be
manifested as decreased drug maximal killing rate (Vmax in
Equation 1) in the methodology; interesting this parameter was
found to be a far more potent determinant of resistance than the
IC50 [13]. It would be possible to re-run the above simulations
altering Vmax rather than IC50 but we chose to use the more
conventional approach in the first instance as we consider this
primarily a computational paper; we shall explore this approach in
future studies applying the methodology more specifically to
malaria.
Malaria differs from many other pathogens in having a distinct
48 hour intracellular cycle that essentially consists of invasion of
red blood cells (RBC), digestion of host haemoglobin, parasite
multiplication within the RBC, cell rupture and re-invasion of new
RBCs. Drugs consequently have different stage specificity profiles
depending on what metabolic processes are occurring in each
stage (for example, many drugs target haemoglobin digestion so
are primarily active against parasites in this stage of their cycle).
Our analyses ignored these drug stage-specificities. It would
however be easy to re-compute the dynamics using one hour time
steps and using a 48 hour array to move parasites through the
48 hour development cycle as done previously [35,36,37]. We
chose not to do so for two main reasons. Firstly, stage specificity
requires that PD parameters be specified for each stage and that
the initial distribution of parasite stages in the infection be
specified. Secondly, and more importantly in our opinion, is that
the PK/PD computations assume instantaneous killing of parasites
depending on current drug concentration whereas, in reality, there
is a delay in killing. The delayed killing can be incorporated into
the methodology by postulating a hypothetical ‘metabolite’ whose
production or elimination is disrupted by the drug, and that
parasite death occurs as a function of metabolite level; the time
taken for metabolite levels to reach ‘lethal’ levels introduces a time-
lag into the killing [38,39]. This is an elegant way of incorporating
a delay but it requires further parameterisation of the metabolite’s
production and elimination, specification of a killing rate as a
function of metabolite level, and calibration against field data.
Patel and colleagues [38] estimated the delay in artemisinin killing
as around 5 hours. A recent study attempted to simulate ACT
dynamics using a stage structured approach and concluded that it
did not match well field data [36]; we are unsurprised because the
short-term dynamics will be critically dependent on stage-specific
PD parameterisation and no time lag was built into the model.
Hence, our approach was to ignore short-term dynamics and run
the enhanced PK/PD methodology, ignoring stage specify and
delayed drug action [40]; the objective was to simulate the fate of
the infection over the longer term rather than the dynamics
immediately post-treatment. Consistency of our results with field
and clinical observations suggest this is a robust approach but it is
important to recognise the alternative modelling approaches can
be designed, and that our enhanced PK/PD methodology can
easily form the basis for an improved stage-specific model run in 1-
hour time steps.
The rationale behind this paper is that combining good quality
field and clinical data into a sophisticated PK/PD model should
allow a thorough investigation of ACT effectiveness in the context
of increasing artemisinin tolerance/resistance. It therefore pro-
vides a methodological framework for clinical pharmacologists to
interpret their results. However the predictive power of mathe-
matical modelling is governed by the crucial step of model
calibration and the availability of comprehensive, good quality
PK/PD data in the literature is surprisingly scarce (Supporting
Information, part 2). This has the potential to limit the usefulness
of models as predictive tools. Given the amount of effort and
resources required to conduct PK/PD studies and that their
explicit aim is usually to improve human therapy, it seems
appropriate to consider how best to report such studies for
maximum impact. We therefore make three specific suggestions
that authors may consider to maximise their studies’ chance of
influencing policy choice. Firstly, all available population PK/PD
data, including those required purely for intermediate calculations
should be reported. For example, terminal elimination rates are
invariably reported but parameters required in their calculation,
for example volumes of distributions (often confounded with
bioavailability) are often omitted [41]. We are uncomfortable with
the rationale underlying the common assertion that DHA is the
main active species during artemisinin treatment (see above and
Figure S2); we would therefore recommend that PK parameters
for parent species such as artesunate and artemether also be
measured and reported. Secondly, the nature and extent of natural
variation in the parameters are vitally important and can result in
some patients developing low drug concentrations possibly leading
to therapeutic failures or high concentrations potentially leading to
toxicity. The distributions (normal, log-normal, etc) with their
associated coefficients of variations (CV) are therefore almost
equally important as their mean values. For example, many
authors cite CV estimates larger than the mean, which obviously
indicates a non-normal distribution: such data are much more
useful if accompanied by their distributions (herein we were forced
to assume they were log-normal). Finally, there are wide variations
in reported mean values between studies; these are generally
ascribed to sampling different populations or age groups but a
more critical appraisal in terms of any impact of different methods
of analysis would also be helpful. An excellent example is that of
Tan et al. [42] who, after describing the population PK of AS and
DHA in healthy patients, compare their results with those of other
AS and DHA PK studies and provide a detailed discussion
explaining how and why the results may differ.
We would emphasise that our choice of specific studies to
parameterise the simulation should not be regarded as prescriptive
or judgemental; as described above, the choice was often
problematic. Few, if any, PK/PD studies produce all the
parameters required to evaluate their impact on therapeutic
outcome. PK studies often focus on a single drug in a combination
and lack local estimates of parasite drug sensitivity, while PD
studies generally lack accompanying PK estimates. Consequently,
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we have focused on developing a methodology that individual
researchers can calibrate as they wish; we provide a mechanism by
which their results can be integrated with the results of other
studies to gauge their implications for drug effectiveness.
Despite the caveats mentioned above, our results and implica-
tions are clear. The kill rate of both artemisinin forms appears to
be important in determining treatment outcome and their IC50’s
are likely to be correlated. AS-MQ is more sensitive to increases in
artemisinin drug resistance than AR-LF with the number of
failures increasing quickly with relatively small increases in AS and
DHA IC50s. Both ACTs show increasing PCT associated with
increasing artemisinin IC50, an observation already seen in the
field [5,6,7,8,9]. Our results suggest this is indicative of a rapid loss
of protection provided by the artemisinins against the partner
drug(s). If, or when, resistance against the partner drug starts to
increase, most plausibly driven by mismatched half-lives
[43,44,45], then a rapid reduction in ACT clinical effectiveness
is likely to occur. We conclude that policies designed to isolate and
minimise the spread of artemisinin resistance are to be greatly
encouraged [26].
Supporting Information
Figure S1 Panels A–C, the simulated PK profiles of the
artemisinins and the relationship between drug concen-
tration and drug killing rate. The simulated PK profiles of
the artemisinin forms given as the parent drug and subsequently
converted to DHA. Given as (A) artesunate or (B) artemether;
generated using the model shown in Figure 1 mathematical
derivation described herein and using the parameters of Table S1.
The timescale and concentrations match well with those observed
in vivo (see, for example, [47,48,49]). Note that DHA is the major
component when dosing with artesunate, but the minor
component when dosing with artemether. Panel C shows the
relationship between drug concentration and killing rate as
described by the Michaelis-Menton Equation 1 in the main text.
All Figures were produced using the default parameter values
given in Table S1.
(TIF)
Figure S2 Panels A–B, the simulated parasite kill curves
of the artemisinins. The simulated parasite kill curves of the
parent artemisinin drug forms (artesunate and artemether) and
their active metabolite DHA. Treatment with (A) artesunate and
(B) artemether. Curves generated using the mathematical
derivation described herein and using the parameters of Table S1.
(TIF)
Figure S3 Panels A–B, changes in drug failure rates
associated with increasing drug resistance when pa-
rameters are varied by 30%. Change in failure rates
associated with increasing AS/AR and DHA IC50 when the
coefficient of variation in all parameters is always 30% (A) AS-MQ
treatment and (B) AR-LF treatment.
(TIF)
Figure S4 Panels A–F, changes in drug failure rates
associated with increasing drug resistance when assum-
ing independent action of the artemisinin components.
Change in failure rates associated with either increasing AS/AR
IC50 (panels A–B), increasing DHA IC50 (panels C–D) or
increasing AS/AR and DHA IC50 (panels E–F), AS-MQ
treatment (left column) and AR-LF treatment (right column)
assuming independent action of the artemisinin components. Note
that failure rates for monotherapies are shown as columns to the
immediate right of the x-axis.
(TIF)
Figure S5 Panels A–F, changes in parasite clearance
times associated with increasing drug resistance when
assuming independent action of the artemisinin compo-
nents. Change in parasite clearance times (PCT) associated with
either increasing AS/AR IC50 (panels A–B), increasing DHA
IC50 (panels C–D) or increasing AS/AR and DHA IC50 (panels
E–F), AS-MQ treatment (left column) and AR-LF treatment (right
column) assuming independent action of the artemisinin compo-
nents. Note that PCTs for monotherapies are shown as columns to
the immediate right of the x-axis.
(TIF)
Figure S6 The standard two-compartment pharmaco-
kinetic model. A standard PK two-compartment model
allowing for drug absorption from the gut (component A) to the
central compartment (component B) at a rate x. The drug is either
eliminated from the body at a rate k or exchanged with a
peripheral compartment (component C)), the drug leaves the
central compartment at a rate y and returns at a rate z.
(TIF)
Table S1 Mean antimalarial drug parameters and their
associated distributions. Mean antimalarial drug parameters
for artesunate-mefloquine and artemether-lumefantrine combina-
tion therapies. The amount of variation (i.e. CV) is given in square
brackets.
(DOCX)
Table S2 Correlations between the IC50s of five anti-
malarial drugs. Data describing the half-maximal inhibitory
concentration (IC50) of 5 different antimalarials measured in 7
different P.falciparum strains by Delves et al. [46], was used to
determine whether the IC50s of the artemisinins are correlated.
(DOCX)
Text S1 Pharmacokinetic model extensions, model
calibration and implementation. Supporting information.
(DOCX)
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